Hence, such targeted therapeutics may constitute a valuable treatment option, in particular in cases where current antibody therapies are ineffective.Antibody-toxins, also termed immunotoxins, were initially derived by chemically coupling bacterial or plant toxins to monoclonal antibodies specific for molecules on the surface of tumor cells.